中国医药(600056)

净利润 + 每股收益

Created with Highcharts 9.1.0

03-3112-3109-3006-3002.557.500.20.40.6

净利润(亿元) 每股收益(元)

    截至2025年第一季度实现净利润2.27亿元，每股收益0.11元。

股东权益 + 未分配利润

Created with Highcharts 9.1.0

03-3112-3109-3006-3006012018072757881

股东权益(亿元) 未分配利润(亿元)

    截至2025年第一季度最新股东权益1433931.53万元，未分配利润779253.93万元。

总资产 + 负债

Created with Highcharts 9.1.0

03-3112-3109-3006-300150300450210220230240

总资产(亿元) 负债(亿元)

    截至2025年第一季度最新总资产3569105.59万元，负债2135174.06万元。

利润表 报告期2025-03-312024-12-312024-09-302024-06-30营业总收入8,262,744,582.7534,148,359,638.9926,099,729,998.417,797,322,228.73营业总成本7,973,445,487.2832,983,445,215.4225,216,783,611.9917,153,291,092.83营业利润304,650,879.12931,567,858.53850,564,674.59606,652,720.96利润总额304,613,642.69953,188,513.89842,783,779604,023,833.45净利润227,200,028.63686,623,882.02620,917,976.67449,756,770.46其他综合收益884,977.29-362,481.48-3,545,260.38-1,457,158.88综合收益总额228,085,005.92686,261,400.54617,372,716.29448,299,611.58 资产负债表 报告期2025-03-312024-12-312024-09-302024-06-30流动资产合计26,788,148,856.2926,370,732,716.9328,878,917,996.9828,691,822,636.82非流动资产合计8,902,906,995.768,910,326,196.618,998,958,623.378,927,573,413.33资产总计35,691,055,852.0535,281,058,913.5437,877,876,620.3537,619,396,050.15流动负债合计17,223,758,138.3817,176,763,537.4519,912,131,853.4319,292,800,192.75非流动负债合计4,127,982,443.793,993,465,112.133,876,990,851.764,357,850,134.22负债合计21,351,740,582.1721,170,228,649.5823,789,122,705.1923,650,650,326.97归属于母公司股东权益合计11,987,780,202.6111,820,515,989.311,657,211,823.4411,569,791,063.03股东权益合计14,339,315,269.8814,110,830,263.9614,088,753,915.1613,968,745,723.18负债和股东权益合计35,691,055,852.0535,281,058,913.5437,877,876,620.3537,619,396,050.15 现金流量表 报告期2025-03-312024-12-312024-09-302024-06-30经营活动现金流入小计7,438,600,455.4236,243,984,709.6826,583,177,927.7617,583,177,308.75经营活动现金流出小计8,920,176,697.8435,238,554,160.0626,903,604,540.1518,269,315,032.28经营活动产生的现金流量净额-1,481,576,242.421,005,430,549.62-320,426,612.39-686,137,723.53投资活动现金流入小计8,187,430.1943,843,014.211,514,517.12144,083.19投资活动现金流出小计65,496,987.21411,499,628.29281,151,821.22200,157,179.81投资活动产生的现金流量净额-57,309,557.02-367,656,614.08-279,637,304.1-200,013,096.62筹资活动现金流入小计1,475,926,683.576,492,003,159.824,208,007,673.323,215,720,287.81筹资活动现金流出小计1,429,227,227.676,750,237,069.634,581,509,564.692,994,248,643.97筹资活动产生的现金流量净额46,699,455.9-258,233,909.81-373,501,891.37221,471,643.84汇率变动对现金及现金等价物的影响-842,648.331,779,865.311,887,281.63321,865.34现金及现金等价物净增加额-1,493,028,991.87381,319,891.04-971,678,526.23-664,357,310.97期末现金及现金等价物余额2,218,549,837.943,711,578,829.812,358,580,412.542,665,901,627.8

网址：中国医药(600056) https://mxgxt.com/news/view/1424538

相关内容

天方药业高管因关联交易等事项被约谈
国家中医药管理局重点实验室聚焦中医药原创性研究
外国友人感受中医药魅力
中国药店－医药电商直播之路
天方药业因关联交易违规遭河南证监局警示
中医药的外国朋友圈越来越大
《国医少年志》中医药文化明星体验真人秀
让年轻人爱上中医药！《国医少年志》圆满收官！
瞭望｜同仁堂携中医药登上国际舞台
儒医互根，契合发展！浅述儒学与中医学的关系中国中医药报官方号

随便看看